
COVID-19 vaccine must be released soon or stock market could drop more than 10%: Goldman Sachs
Getting positive news on the COVID-19 front is essential to maintaining the stock market’s post-election rally, Goldman Sachs believes. …read more […]
Getting positive news on the COVID-19 front is essential to maintaining the stock market’s post-election rally, Goldman Sachs believes. …read more […]
Vaccine developer Pfizer and German partner BioNTech’s coronavirus vaccine is more that 90% effective. Dr. Dara Kass, Yahoo Medical Contributor & Columbia University Associate Professor of Emergency Medicine shares the details. …read more […]
Readers hoping to buy The Charles Schwab Corporation (NYSE:SCHW) for its dividend will need to make their move… …read more […]
CALGARY, AB, Nov. 9, 2020 /CNW/ – Sundial Growers Inc. …read more […]
Shares jump after Pfizer says analysis indicates its coronavirus vaccine offers 90% protection. …read more […]
(Bloomberg) — Investors cashed out of companies that benefited from virus-induced lockdowns after promising results for a Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE reawakened hopes that a return to normal is on the horizon.Zoom Video Communications Inc. plunged 16% in early trading, while Peloton Interactive Inc. slumped 13% and Netflix Inc. was down 5% as investors piled into risk assets and dumped shares of firms that have been winners during global lockdowns. Futures contracts on the Nasdaq reversed earlier gains and fluctuated.“The rotation that the market is doing is beyond any imagination with Nasdaq in negative territory …read more […]
A week ago, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) came out with a strong set of quarterly numbers that could… …read more […]
Wall Street analysts largely believe the panel’s near-unanimous votes against the drug, aducanumab, make it difficult for the FDA to go against the panel. “Approving aducanumab, in the face of such an overwhelmingly negative vote and commentary, is virtually impossible and would destroy the agency’s reputation at a very tenuous time for the regulator, ahead of potential actions on COVID vaccines,” Baird analyst Brian Skorney said. The FDA is expected to make its decision on aducanumab by March and is not obligated to follow the recommendations of the panel, but usually does. …read more […]
(Bloomberg) — Biogen Inc. shares plunged early on Monday and analysts braced for further declines after a U.S. Food and Drug Administration advisory panel harshly judged the efficacy of the company’s experimental Alzheimer’s disease therapy, dimming prospects it will be approved by the agency.The stock fell 32% as futures trading resumed on Nasdaq after shares were halted on Friday.Wall Street firms didn’t mince words over the weekend about the panel’s findings, which was that data from a single clinical trial with positive results was insufficient to show the treatment worked. Raymond James called it a “disaster,” while Baird wrote that …read more […]
Apple Inc on Tuesday is expected to unveil new Mac computers using its own in-house processor chips, a move that could reignite a race to control the market for desktop and laptop chips and benefit players such as Qualcomm Inc. The market has been dominated by Intel Corp and Advanced Micro Devices Inc since 2006, when Apple joined most other major computer makers in using chips based on Intel’s ‘x86’ computing architecture. On Tuesday Apple is expected to start a two-year process of ending its nearly 15-year relationship with Intel by introducing Mac computers with Apple-designed chips based …read more […]
(Bloomberg) — Oil in London jumped by the most since June as Pfizer Inc. reported a potential Covid-19 vaccine breakthrough.Futures in London rose by 8.3% to $42.74 a barrel following a broad rally in equity markets, while West Texas Intermediate also jumped.The vaccine being developed by Pfizer and BioNTech SE prevented more than 90% of infections in a study of tens of thousands of volunteers, the most encouraging scientific advance so far in the battle against the coronavirus.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P. …read more […]
* 1 Canadian Medical Position by Cannabis Net Revenue & Strong International Medical Growth * Cannabis Net Revenue of $67.8 million, Adjusted Gross Margin of 48%, or 52% Excluding Nordic 1 Ramp Up Costs * Achieved Targeted SG&A; During Q1 2021NYSE | TSX: ACBEDMONTON, AB, Nov. …read more […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.